L-arginine
Small molecule in Homo sapiens that 2 drugs act on.
- Drugs that act on it: 2
- Approved: 1
- In phases 1 to 3: 1
- Sponsors: 2
Who is on it, and how far along
Every drug ChEMBL records acting on this target, by the furthest stage it has reached for any use, coloured by modality.
How to read this
Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
- Protein or peptide 2
| Pegzilarginase | Approved | Immedica Pharma | Protein or peptide | Hydrolytic enzymeL-arginine hydrolytic enzyme | 0 |
| Pegargiminase | Phase 3 | Polaris Group | Protein or peptide | Hydrolytic enzymeL-arginine hydrolytic enzyme | 6 |
| A Clinical Study of PA5 in Patients With Advanced Solid Tumors | Pegargiminase | Phase 1 | Recruiting | Chongqing Peg-Bio Biopharm Co., Ltd. | Jul 14, 2026 |
| Combination ADI-PEG 20, TMZ, and RT for Treatment of Newly Diagnosed High-grade Glioma (HGG) | Pegargiminase | Phase 1 / Phase 2 | Not yet recruiting | Sabine Mueller, MD, PhD | Feb 5, 2026 |
| Phase I/II Study of PEGylated Arginine Deiminase (ADI-PEG20) With Carboplatin and Cabazitaxel in Men With Aggressive Variant Prostate Cancers (AVPC) | Pegargiminase | Phase 1 / Phase 2 | Recruiting | M.D. Anderson Cancer Center | Oct 17, 2023 |
| Study of ADI-PEG 20 Versus Placebo in Subjects With NASH | Pegargiminase | Phase 2 | Recruiting | Polaris Group | May 6, 2023 |
| Study of ADI-PEG 20 Versus Placebo in Subjects With High Arginine Level and Unresectable Hepatocellular Carcinoma | Pegargiminase | Phase 3 | Recruiting | Polaris Group | Apr 8, 2022 |
| A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma | Pegargiminase | Phase 2 / Phase 3 | Recruiting | Global Coalition for Adaptive Research | May 31, 2019 |
Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL4651302, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. ChEMBL and Open Targets